Bio-Rad Ratings Affirmed by Fitch | GenomeWeb

NEW YORK (GenomeWeb News) – Fitch Ratings today affirmed Bio-Rad's ratings, noting the firm's stability and strong cash position but warning against continued macroeconomic headwinds.

Included in the ratings is a BBB- for Issuer Default Rating; BBB- for senior secured bank facility; BBB- for senior unsecured notes; and BB+ for senior subordinated notes.

The rating outlook for the Hercules, Calif.-based company is stable, Fitch said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genetic history of HIV in the US, and more.

There are a few projects aimed at addressing the lack of diversity in genomic research, Technology Review reports.

A national assessment shows that US students lag in the sciences, but suggests that achievement gaps are narrowing.

Harvard's George Church discusses HGP-write with the Journal of the American Medical Association.